An Open-Label, Randomized, Single Dose, Two-Period Crossover Study to Demonstrate Bioequivalence Between the Controlled Release Paroxetine Tablet (37.5 mg) Manufactured at Cidra and Mississauga.
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Paroxetine (Primary)
- Indications Depressive disorders
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 25 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Mar 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 26 Sep 2008 New trial record.